PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
27398225-1	2016	BACKGROUND: Regorafenib and its metabolites may inhibit the activities of several CYP or UDP-glucuronosyltransferase isoforms, including that of CYP2C9.	regorafenib	12-23	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	145-151	
27398225-2	2016	Therefore, pharmacological agents that are CYP2C9 substrates may show elevated circulating levels and enhanced drug efficacy when concurrently used with regorafenib.	regorafenib	153-164	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	43-49	
27398225-3	2016	Previous studies showed that the area under the plasma concentration-time curve of warfarin, which is the substrate for CYP2C9, increased upon co-administration of regorafenib.	regorafenib	164-175	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	120-126